Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2010

View Archived Issues

Promising phase I data on CAL-101 in hematological malignancies disclosed

Indian scientists claim new ketolides as antibacterial agents

Pfizer develops new glucocorticoid receptor agonists

Leo Pharma divulges new positive modulators of calcium-sensing receptor

New histamine H3 receptor antagonists presented by Evotec

Japan Tobacco patents new inhibitors of macrophage colony-stimulating factor 1 receptor

Sunesis begins phase III vosaroxin trial in acute myeloid leukemia

PTC Therapeutics completes enrollment of phase III Ataluren trial in cystic fibrosis

FDA grants orphan drug status to rFVIIIFc for hemophilia A treatment

VBL begins phase II study of VB-201 in patients with elevated hsCRP levels

AstraZeneca and Abbott discontinue development of Certriad for mixed dyslipidemia

Lentiviral vector-based vaccine VRX-1116 shows promise in HIV therapy

Lower risk of metabolic complications seen with darunavir vs. atazanavir plus ritonavir in HIV

TRPV4 antagonists hold promise for the treatment of bladder dysfunction

Combination of AZD-0530 and anastrozole shows promise in hormone receptor-positive breast cancer

Living Cell Technologies adds patients to Diabecell trial in New Zealand

FDA approves Amturnide, a triple-combination pill, to treat high blood pressure

Merck receives FDA approval for new indications for HPV vaccine Gardasil

FDA issues complete response letter for acetadote supplemental NDA

Gilead stops phase III trial of ambrisentan in IPF after interim analysis

Amylin and Lilly submit NDA for Byetta as an add-on therapy to basal insulin

Medicago provides phase II update on avian influenza vaccine

Intercell begins phase I trial of IC-84 against Clostridium difficile infections

Threshold reports phase I data for TH-302 in patients with advanced leukemia

Pfizer submits supplemental NDAs to FDA and EMA for Prevnar 13

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...